Invokana

(Canagliflozin)

ApprovedSmall molecule

Canagliflozin is used to help control blood sugar levels in people with type 2 diabetes. It works by helping the kidneys remove excess sugar through urine.[2] Invokana is currently approved and in use across 25 indications[4].[1]

Invokana is one of 538 small molecule programs targeting Acute Ischemic Stroke From Large Vessel Occlusion. It is currently in Approved.

Indications

120

Total Trials

Active Trials

537

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Acute Ischemic Stroke From Large Vessel OcclusionNot yet recruiting

Renal InsufficiencyApproved

ObesityApproved

Chronic Kidney DiseaseApproved

Hepatic FailureApproved

Diabetes MellitusActive, not recruiting

Fatty Liver DiseaseActive, not recruiting

Myocardial FibrosisActive, not recruiting

Type 1 DiabetesApproved

Pancreatic CarcinomaActive, not recruiting

Acute Ischemic Stroke From Large Vessel OcclusionApproved

Not yet recruiting

Renal InsufficiencyApproved

Approved

ObesityApproved

Approved

Chronic Kidney DiseaseApproved

Approved

Hepatic FailureApproved

Approved

Diabetes MellitusApproved

Active, not recruiting

Fatty Liver DiseasePreclinical

Active, not recruiting

Myocardial FibrosisApproved

Active, not recruiting

Type 1 DiabetesApproved

Approved

Pancreatic CarcinomaPreclinical

Active, not recruiting

Showing 10 of 25 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Invokana

WWim Janssens

Approved

1 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Recruiting

Vascular Inflammation

NCT05427084

Phase 2Recruiting

Study completion

NCT05507892

Phase 1Active, not recruiting

Tics

NCT02891954

Q1 2027

N/ANot yet recruiting

Pancreatic Carcinoma

NCT05903703

Q4 2027

Phase 2Active, not recruiting

Breast Cancer

NCT05090358

Post-ApprovalNot yet recruiting

Study completion

NCT06858436

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus22 trials

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03249506·25,358 enrolled

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01989754·5,813 enrolled

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01381887·37 enrolled

Show 19 more trials

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 4·NCT02220920·146 enrolled

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01340664·279 enrolled

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01128985·39 enrolled

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02009488·59 enrolled

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01381900·678 enrolled

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT02025907·218 enrolled

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01106651·716 enrolled

A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03170518·171 enrolled

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01809327·1,186 enrolled

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT03267576·64 enrolled

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02000700·17 enrolled

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 4·NCT02622113·139 enrolled

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 4·NCT02227849·71 enrolled

A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01483781·36 enrolled

A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01273558·28 enrolled

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04014192·40 enrolled

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01064414·272 enrolled

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03492580·714,582 enrolled

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01939496·171 enrolled

Metformin18 trials

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00968812·1,452 enrolled

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02065752·2 enrolled

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02077803·47 enrolled

Show 15 more trials

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01508195·64 enrolled

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02846506·44 enrolled

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01508182·64 enrolled

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02073227·52 enrolled

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01106690·344 enrolled

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02865668·44 enrolled

The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01106625·469 enrolled

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02220218·2 enrolled

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02851212·44 enrolled

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02071368·3 enrolled

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02221180·2 enrolled

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02851095·44 enrolled

Glycemic Durability After Metformin Failure

Unknown status·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT02142309·450 enrolled

A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01273571·18 enrolled

A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes

Completed·JJohnson & Johnson Private Limited·Phase 4·NCT04288778·276 enrolled

Type 2 Diabetes10 trials

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Terminated·TThe Cleveland Clinic·Phase 4·NCT02912455·16 enrolled

A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

Completed·JJohnson & Johnson Private Limited··NCT03604224·178 enrolled

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00642278·451 enrolled

Show 7 more trials

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT02354222·154 enrolled

Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes

Unknown status·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT05856578·60 enrolled

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03136484·788 enrolled

The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin

Withdrawn·JJoslin Diabetes Center·Phase 4·NCT02597309

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT02354235·138 enrolled

TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

Completed·RRoyal Devon and Exeter NHS Foundation Trust·Phase 4·NCT02653209·525 enrolled

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

Completed·GGeorge Washington University·Phase 4·NCT02964585·34 enrolled

Tics8 trials

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01748526·16 enrolled

A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01718652·18 enrolled

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01733108·29 enrolled

Show 5 more trials

Genetics of Response to Canagliflozin

Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT02891954·700 enrolled

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01714206·18 enrolled

A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01395927·14 enrolled

A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01294631·30 enrolled

A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01428284·14 enrolled

Treatment3 trials

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Withdrawn·UUniversité de Sherbrooke·N/A·NCT03298009

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01137812·756 enrolled

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01106677·1,284 enrolled

47 more indications

Alcoholic Fatty Liver Disease2 trials

Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT05422092·80 enrolled

Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University··NCT05513729·80 enrolled

Heart Failure2 trials

Canagliflozin in Patients With Acute Decompansted Heart Failure

Completed·OOctober 6 University·Phase 3·NCT05364190·142 enrolled

A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04252287·476 enrolled

Weight loss2 trials

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00650806·376 enrolled

Mechanisms of Weight Loss With SGLT2 Inhibition

Completed·—·Phase 4·NCT02360774·30 enrolled

Interaction2 trials

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01756417·18 enrolled

A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01195324·14 enrolled

Function2 trials

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01759576·40 enrolled

A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01186588·24 enrolled

Diabetic Nephropathy2 trials

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02065791·4,401 enrolled

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT03436693·308 enrolled

Adult2 trials

The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01343290·24 enrolled

A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01286103·34 enrolled

Colorectal Cancer1 trial

Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer

Recruiting·WWest China Hospital·Phase 1·NCT07076823·15 enrolled

PreDiabetes1 trial

Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.

Unknown status·Xxiaolong zhao·N/A·NCT05135039·218 enrolled

Drug1 trial

Cognitive Protective Effect of Newer Antidiabetic Drugs

Unknown status·—··NCT05347459·100 enrolled

Type 1 Diabetes1 trial

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

Completed·YYale University·N/A·NCT02673138·10 enrolled

Type 1 Diabetes Mellitus1 trial

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02139943·352 enrolled

Hemodynamic1 trial

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Withdrawn·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT03190798

Cardiovascular1 trial

CANVAS - CANagliflozin cardioVascular Assessment Study

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01032629·4,330 enrolled

Oral1 trial

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01714193·30 enrolled

Obese1 trial

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01756404·80 enrolled

Patients With Advanced Solid Tumors1 trial

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Unknown status·PPetra Pharma·Phase 1/2·NCT04073680·60 enrolled

Hyperinsulinemic Hypoglycemia1 trial

Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·N/A·NCT04720859·40 enrolled

Statin1 trial

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01821027·22 enrolled

Adult Subject1 trial

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Completed·LLexicon Pharmaceuticals·Phase 1·NCT01916863·25 enrolled

CAR1 trial

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01787357·60 enrolled

Obesity1 trial

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Completed·NNational Cheng-Kung University Hospital·N/A·NCT05764811·40 enrolled

Completed·VVirginia Commonwealth University·Phase 4·NCT02920918·36 enrolled

Overweight1 trial

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02243202·335 enrolled

Metabolism1 trial

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT02404870·67 enrolled

Elderly1 trial

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

Unknown status·CCenter for Outcomes Research and Clinical Epidemiology, Italy·Phase 4·NCT04796428·1,167 enrolled

SGLT2 Inhibitors1 trial

Pharmacogenetics of SGLT2 Inhibitors

Terminated·UUniversity of Maryland, Baltimore·Phase 4·NCT02462421·30 enrolled

T2DM1 trial

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

Completed·UUniversity of Leicester·Phase 4·NCT02694263·25 enrolled

RCT1 trial

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Completed· AstraZeneca logo

AstraZeneca··NCT06099067·239,990 enrolled

Vascular Inflammation1 trial

Canagliflozin Targeting Vascular Inflammation

Recruiting·OOttawa Heart Institute Research Corporation·Phase 2/3·NCT05427084·24 enrolled

Cognitive Function1 trial

Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)

Completed·TThird Military Medical University·Phase 3·NCT04304261·100 enrolled

Kidney Disease1 trial

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

Recruiting·NNational Taiwan University Hospital·Phase 2·NCT06528405·264 enrolled

CLE1 trial

Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01665638·10 enrolled

Dapagliflozin1 trial

A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01877889·60 enrolled

Renal Disease1 trial

Canagliflozin in Advanced Renal Disease With MRI Endpoints

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT06182839·92 enrolled

Women1 trial

CANA/Met in Non-diabetic Women With PCOS

Completed·SShengjing Hospital·Phase 1/2·NCT04973891·52 enrolled

Pancreatic Carcinoma1 trial

Canagliflozin With Gemcitabine in Pancreatic Carcinoma

Not yet recruiting·ZZhang Xiaofeng,MD·N/A·NCT05903703·20 enrolled

Myocardial fibrosis1 trial

Canagliflozin and Myocardial Fibrosis

Completed·SShanghai Zhongshan Hospital·Phase 4·NCT05367063·45 enrolled

Polycystic Ovary Syndrome1 trial

Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome

Unknown status·PPing Li,MD·Phase 4·NCT06256289·50 enrolled

Monotherapy1 trial

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01081834·678 enrolled

Diabetes1 trial

Replication of the CANVAS Diabetes Trial in Healthcare Claims

Completed·—··NCT03936010·152,202 enrolled

Solid Tumor1 trial

Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer

Recruiting·WWest China Hospital·Phase 1·NCT07703163·15 enrolled

Diabetes Mellitus, Type 21 trial

Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes.

Completed·FFundación para la Investigación del Hospital Clínico de Valencia·Approved·NCT06851962·92 enrolled

Breast Cancer1 trial

Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05090358·15 enrolled

Unspecified6 trials

SGLT2 Inhibitor Utilization Re-perfusion Therapy

Not yet recruiting·TTaichung Veterans General Hospital·Phase 4·NCT06858436·150 enrolled

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01340677·24 enrolled

A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01281579·27 enrolled

Show 3 more trials

Canagliflozin-Mealtime Insulin Rescue

Unknown status·FFoundation for Atlanta Veterans Education and Research, Inc.·Phase 4·NCT02624908·40 enrolled

Renal Mechanism of SGLT2 Inhibition

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05507892·40 enrolled

A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01157000·9 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 29, 2013

INVOKANA

NDA NDA204042

Sources

References

[1]
ClinicalTrials.gov — 120 trial records for Canagliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Invokana drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Canagliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Canagliflozin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA204042). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Wim Janssens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Sodium/glucose Cotransporter 2 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: WWim Janssens

Invokana

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Trials by Indication[1]

Type 2 Diabetes Mellitus22 trials

Metformin18 trials

Type 2 Diabetes10 trials

Tics8 trials

Treatment3 trials

Alcoholic Fatty Liver Disease2 trials

Heart Failure2 trials

Weight loss2 trials

Interaction2 trials

Function2 trials

Diabetic Nephropathy2 trials

Adult2 trials

Colorectal Cancer1 trial

PreDiabetes1 trial

Drug1 trial

Type 1 Diabetes1 trial

Type 1 Diabetes Mellitus1 trial

Hemodynamic1 trial

Cardiovascular1 trial

Oral1 trial

Obese1 trial

Patients With Advanced Solid Tumors1 trial

Hyperinsulinemic Hypoglycemia1 trial

Statin1 trial

Adult Subject1 trial

CAR1 trial

Obesity1 trial

Fibrosis1 trial

Type 2 Diabetic Patients1 trial

Systolic Heart Failure1 trial

Overweight1 trial

Metabolism1 trial

Elderly1 trial

SGLT2 Inhibitors1 trial

T2DM1 trial

RCT1 trial

Vascular Inflammation1 trial

Cognitive Function1 trial

Kidney Disease1 trial

CLE1 trial

Dapagliflozin1 trial

Renal Disease1 trial

Women1 trial

Pancreatic Carcinoma1 trial

Myocardial fibrosis1 trial

Polycystic Ovary Syndrome1 trial

Monotherapy1 trial

Diabetes1 trial

Solid Tumor1 trial

Diabetes Mellitus, Type 21 trial

Breast Cancer1 trial

Unspecified6 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News